Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
TFF Pharmaceuticals (Nasdaq: TFFP) announces positive preclinical data published in the Journal of Drug Delivery Science and Technology, validating its Thin Film Freezing (TFF) technology as a superior approach for formulating dry powders for pulmonary drug delivery. The study compared TFF inhalational dry powders with jet-milling and spray-drying technologies in a rat model, demonstrating:
Enhanced uniform drug distribution in the lungs
Lower airway-to-lung distribution ratio
Rapid disaggregation of particles and subsequent movement of TFF nanoaggregates
TFF processed voriconazole dry powder showed the most homogeneous distribution in lung tissue, with the lowest airway-to-lung voriconazole deposition ratio (1.27) compared to spray-dried (1.76) and jet-milled (2.73) powders. These results suggest TFF inhalational dry powders may enhance treatment efficiency and reduce toxicity for lung diseases.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
1696 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2314Followers
    106Following
    24KVisitors
    Follow